You are here: Industry Insights > Market News > Promethazine by Strides Shasun approved by USFDA

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Vibegron Intermediate CAS:1421271-01-3

Food Grade Fish Collagen

Vibegron Intermediate CAS:1295539-30-8

Vibegron Intermediate CAS:1426235-01-9

Vibegron Intermediate CAS:163625-46-5

Vibegron Intermediate

Promethazine by Strides Shasun approved by USFDA

biospectrumasiaJuly 04, 2017

Tag: Promethazine , USFDA

Favorites

Strides Shasun has recently received an approval from the United States Food & Drug Administration (USFDA) for Promethazine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg.

According to IMS data, the US market for Promethazine Hydrochloride Tablets USP, 12.5 mg, 25 mg, and 50 mg is approximately $ 17 million.

The product will be manufactured at the company’s flagship facility at Bangalore and marketed by Strides Pharma Inc. in the US Market.

Promethazine Hydrochloride Tablet is used to prevent and treat nausea and vomiting related to certain conditions and also to treat allergy symptoms such as rash, itching, and runny nose.

Previous:TissueGene awarded $750,000 Maryland Stem Cell Grant for Invossa clinical study

Next:Amgen’s uncontrolled LDL cholesterol lowering drug available in Singapore

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Promethazine by Strides Shasun approved by USFDA | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Promethazine by Strides Shasun approved by USFDA

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Promethazine by Strides Shasun approved by USFDA

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>